South Korea FDA Warns Again About GSK's Avandia Diabetes Drug
This article was originally published in PharmAsia News
Executive SummarySouth Korea's FDA issued another warning advising heart patients about GlaxoSmithKline's Avandia (rosiglitazone) for treating diabetes
You may also be interested in...
A draft guidance document by the US FDA that tackles medical device cybersecurity will likely be issued in the next several months, says Linda Ricci, a health scientist for the agency’s Office of Device Evaluation. Check out her comments on cybersecurity here.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.